THERAPEUTIC PROTEINS AND ORAL VACCINES MARKET ANALYSIS

Market Challenges And Opportunities

Global Therapeutic Proteins and Oral Vaccines Market– Drivers

Rising Number of Clinical Trials by Major Companies

• The increasing number of pharmaceutical companies are focusing on research and development for the treatment of various diseases such as growth hormone deficiency (GHD) in young children and others, and this is expected to aid in growth of the market over the forecast period. For instance, in October 2019, OPKO Health Inc., a medication company,  and Pfizer Inc., a pharmaceutical company, announced that the global Phase 3 trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN (somatropin) for injection, as per measured by annual height velocity at 12 months.
• Moreover, research institutes and academic institutes are focusing on research and development for the treatment coronavirus infection affecting individuals globally.
• For instance, in March 2020, Migal Galilee Research Institute Ltd, the research and development centre of MigVax Ltd., announced that a new vaccine they developed for a deadly virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV (and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Global Therapeutic Proteins and Oral Vaccines Market - Key Players

Major players operating in the global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, Eli Lilly and Company, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc.